- Home
- Neonatal Jaundice Management Market
Global Neonatal Jaundice Management Market - Industry Trends and Forecast to 2028
- Published Date: September, 2022 | Report ID: CLS-93 | No of pages: 291 | Format:
Global neonatal jaundice management market is projected to register a healthy CAGR of 6.4% in the forecast period of 2021 to 2028. The new market report contains data for the historic year 2019, the base year of calculation is 2020 and the forecast period is 2021 to 2028.
Market Segmentation
Global Neonatal Jaundice Management Market, By Management (Diagnosis and Treatment), Type (Primary Care and Secondary Care), Technology (Light-Emitting Diode Light Sources, Fluorescent, Halogen and Fiberoptic), End User (Hospitals, Clinics, Ambulatory Surgical Centers, Home Users and Others), Distribution Channel (Direct Tender, Retail Sales and Third Party Distribution), Country (U.S., Canada, Mexico, Germany, U.K., France, Italy, Spain, Netherlands, Russia, Switzerland, Turkey, Rest of Europe, Japan, China, Australia, India, South Korea, Singapore, Indonesia, Thailand, Malaysia, Philippines, Rest of Asia-Pacific, Brazil, Argentina, Rest of South America, Saudi Arabia, South Africa, UAE, Israel, Egypt and Rest of Middle East and Africa) Industry Trends and Forecast to 2028
Some of the major factors contributing to the growth of the neonatal jaundice management market are:
Rising patient population suffering from neonatal jaundice.
Increasing awareness about the neonatal jaundice.
Market Players
The key market players for the neonatal jaundice management market are listed below:
Atom Medical Corp.
avihealthcare
Ibis Medical
Natus Medical Incorporated.
DAVID
Signify Holding.
Weyer GmbH
nice Neotech Medical Systems Pvt. Ltd.
Phoenix Medical Systems
Aeroflow, Inc.
Zhengzhou Dison Instrument And Meter Co., Ltd
GENERAL ELECTRIC COMPANY
Neolight
Ardo
NeoMedLight
S S TECHNOMED(P)LTD
Drgerwerk AG & Co. KGaA
Braun & Co. Limited
HERBERT WALDMANN GMBH & CO. KG
GINEVRI srl
Shvabe Zurich GmbH
TABLE OF CONTENT
TABLE OF CONTENTS
1 INTRODUCTION 34
1.1 OBJECTIVES OF THE STUDY 34
1.2 MARKET DEFINITION 34
1.3 OVERVIEW OF GLOBAL NEONATAL JAUNDICE MANAGEMENT MARKET 34
1.4 LIMITATIONS 36
1.5 MARKETS COVERED 36
2 MARKET SEGMENTATION 39
2.1 MARKETS COVERED 39
2.2 GEOGRAPHICAL SCOPE 40
2.3 YEARS CONSIDERED FOR THE STUDY 41
2.4 CURRENCY AND PRICING 41
2.5 DBMR TRIPOD DATA VALIDATION MODEL 42
2.6 MULTIVARIATE MODELLING 45
2.7 MANAGEMENT LIFELINE CURVE 45
2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 46
2.9 DBMR MARKET POSITION GRID 47
2.10 VENDOR SHARE ANALYSIS 48
2.11 MARKET MANAGEMENT COVERAGE GRID 49
2.12 SECONDARY SOURCES 50
2.13 ASSUMPTIONS 50
3 EXECUTIVE SUMMARY 51
4 GLOBAL NEONATAL JAUNDICE MANAGEMENT MARKET: LAWS AND REGULATIONS 57
5 MARKET OVERVIEW 61
5.1 DRIVERS 63
5.1.1 RISING PATIENT POPULATION SUFFERING FROM NEONATAL JAUNDICE 63
5.1.2 LARGE NUMBER OF RISK FACTORS 63
5.1.3 RISING NUMBER OF NEW-BORN INFANTS 65
5.1.4 INCREASE IN PRETERM BIRTH 66
5.1.5 AWARENESS ABOUT NEONATAL JAUNDICE AMONG THE POPULATION 67
5.2 RESTRAINTS 68
5.2.1 SIDE-EFFECTS RELATED TO PHOTOTHERAPY 68
5.2.2 PRODUCT RECALLS 69
5.2.3 LIMITED ADOPTION OF NEONATAL JAUNDICE MANAGEMENT 69
5.3 OPPORTUNITIES 70
5.3.1 INCREASING HEALTHCARE EXPENDITURE 70
5.3.2 TECHNOLOGICAL ADVANCEMENT IN DIAGNOSIS AND TREATMENT 71
5.3.3 INCREASING DISPOSABLE INCOME 72
5.3.4 INCREASE IN AGREEMENTS AND ACQUISITIONS 72
5.4 CHALLENGES 73
5.4.1 COMPLICATIONS RELATED TO NEONATAL JAUNDICE 73
5.4.2 LACK OF SKILLED PROFESSIONALS 74
5.4.3 DIAGNOSIS OF NEONATAL JAUNDICE 74
6 COVID-19 IMPACT ON GLOBAL NEONATAL JAUNDICE MANAGEMENT MARKET IN HEALTHCARE INDUSTRY 75
6.1 PRICE IMPACT 75
6.2 IMPACT ON DEMAND 75
6.3 IMPACT ON SUPPLY CHAIN 76
6.4 STRATEGIC DECISION FOR MANUFACTURERS / SERVICE PROVIDERS 76
6.5 CONCLUSION 78
7 GLOBAL NEONATAL JAUNDICE MANAGEMENT MARKET, BY MANAGEMENT 79
7.1 OVERVIEW 80
7.2 DIAGNOSIS 83
7.2.1 TRANSCUTANEOUS BILIRUBINOMETER (TCB) 84
7.2.2 TOTAL SERUM BILIRUBIN (TSB) 84
7.2.3 VISUAL ASSESSMENT 84
7.3 TREATMENT 84
7.3.1 PHOTOTHERAPY 85
7.3.1.1 LED PHOTOTHERAPY 85
7.3.1.2 FIBREOPTIC PHOTOTHERAPY 86
7.3.1.3 CONVENTIONAL PHOTOTHERAPY 86
7.3.1.3.1 CONVENTIONAL PHOTOTHERAPY WITH COMPACT FLUORESCENT LAMP 86
7.3.1.3.2 CONVENTIONAL PHOTOTHERAPY WITH FLUORESCENT LAMP 86
7.3.1.3.2.1 FULL-BODY PHOTOTHERAPY 86
7.3.1.3.2.2 PARTIAL-BODY PHOTOTHERAPY 87
7.3.2 EXCHANGE TRANSFUSION 87
7.3.3 INTRAVENOUS IMMUNOGLOBULIN 87
7.3.4 OTHERS 87
8 GLOBAL NEONATAL JAUNDICE MANAGEMENT MARKET, BY TYPE 88
8.1 OVERVIEW 89
8.2 PRIMARY CARE 92
8.3 SECONDARY CARE 92
9 GLOBAL NEONATAL JAUNDICE MANAGEMENT MARKET, BY TECHNOLOGY 94
9.1 OVERVIEW 95
9.2 LIGHT-EMITTING DIODE LIGHT SOURCES 98
9.3 FIBEROPTIC 98
9.4 FLUORESCENT 99
9.5 HALOGEN 100
10 GLOBAL NEONATAL JAUNDICE MANAGEMENT MARKET, BY END USER 101
10.1 OVERVIEW 102
10.2 HOSPITALS 105
10.3 CLINICS 105
10.4 HOME USERS 106
10.5 AMBULATORY SURGICAL CENTERS 106
10.6 OTHERS 107
11 GLOBAL NEONATAL JAUNDICE MANAGEMENT MARKET, BY DISTRIBUTION CHANNEL 109
11.1 OVERVIEW 110
11.2 DIRECT TENDERS 113
11.3 RETAIL SALES 113
11.4 THIRD PARTY DISTRIBUTION 114
12 GLOBAL NEONATAL JAUNDICE MANAGEMENT MARKET BY GEOGRAPHY 115
12.1 OVERVIEW 115
12.2 NORTH AMERICA 120
12.2.1 U.S. 126
12.2.2 CANADA 129
12.2.3 MEXICO 132
12.3 EUROPE 135
12.3.1 GERMANY 141
12.3.2 U.K. 144
12.3.3 FRANCE 147
12.3.4 ITALY 150
12.3.5 SPAIN 153
12.3.6 NETHERLANDS 156
12.3.7 RUSSIA 159
12.3.8 SWITZERLAND 162
12.3.9 TURKEY 165
12.3.10 REST OF EUROPE 168
12.4 ASIA-PACIFIC 169
12.4.1 CHINA 176
12.4.2 JAPAN 179
12.4.3 INDIA 182
12.4.4 AUSTRALIA 185
12.4.5 SOUTH KOREA 188
12.4.6 SINGAPORE 191
12.4.7 MALAYSIA 194
12.4.8 THAILAND 197
12.4.9 INDONESIA 200
12.4.10 PHILIPPINES 203
12.4.11 REST OF ASIA-PACIFIC 206
12.5 SOUTH AMERICA 207
12.5.1 BRAZIL 213
12.5.2 ARGENTINA 216
12.5.3 REST OF SOUTH AMERICA 219
12.6 MIDDLE EAST AND AFRICA 220
12.6.1 SOUTH AFRICA 227
12.6.2 SAUDI ARABIA 230
12.6.3 UAE 233
12.6.4 ISRAEL 236
12.6.5 EGYPT 239
12.6.6 REST OF MIDDLE EAST AND AFRICA 242
13 GLOBAL NEONATAL JAUNDICE MANAGEMENT MARKET: COMPANY LANDSCAPE 243
13.1 COMPANY SHARE ANALYSIS: GLOBAL 243
13.2 COMPANY SHARE ANALYSIS: NORTH AMERICA 244
13.3 COMPANY SHARE ANALYSIS: EUROPE 245
13.4 COMPANY SHARE ANALYSIS: ASIA-PACIFIC 246
14 SWOT 247
15 COMPANY PROFILES 248
15.1 SIGNIFY HOLDING 248
15.1.1 COMPANY SNAPSHOT 248
15.1.2 REVENUE FINANCIALS 248
15.1.3 COMPANY SHARE ANALYSIS 249
15.1.4 PRODUCT PORTFOLIO 249
15.1.5 RECENT DEVELOPMENTS 249
15.2 GE HEALTHCARE (A SUBSIDIARY OF GENERAL ELECTRIC COMPANY) 251
15.2.1 COMPANY SNAPSHOT 251
15.2.2 RECENT FINANCIALS 251
15.2.3 COMPANY SHARE ANALYSIS 252
15.2.4 PRODUCT PORTFOLIO 252
15.2.5 RECENT DEVELOPMENTS 252
15.3 ATOM MEDICAL CORP. 254
15.3.1 COMPANY SNAPSHOT 254
15.3.2 COMPANY SHARE ANALYSIS 254
15.3.3 PRODUCT PORTFOLIO 254
15.3.4 RECENT DEVELOPMENTS 255
15.4 NATUS MEDICAL INCORPORATED 256
15.4.1 COMPANY SNAPSHOT 256
15.4.2 RECENT FINANCIALS 256
15.4.3 COMPANY SHARE ANALYSIS 257
15.4.4 PRODUCT PORTFOLIO 257
15.4.5 RECENT DEVELOPMENTS 257
15.5 DRAGERWERK AG & CO. KGAA 259
15.5.1 COMPANY SNAPSHOT 259
15.5.2 RECENT FINANCIALS 259
15.5.3 PRODUCT PORTFOLIO 260
15.5.4 RECENT DEVELOPMENT 260
15.6 HERBERT WALDMANN GMBH & CO. KG 261
15.6.1 COMPANY SNAPSHOT 261
15.6.2 PRODUCT PORTFOLIO 261
15.6.3 RECENT DEVELOPMENTS 261
15.7 AEROFLOW, INC. 263
15.7.1 COMPANY SNAPSHOT 263
15.7.2 PRODUCT PORTFOLIO 263
15.7.3 RECENT DEVELOPMENT 263
15.8 ARDO 264
15.8.1 COMPANY SNAPSHOT 264
15.8.2 PRODUCT PORTFOLIO 264
15.8.3 RECENT DEVELOPMENT 264
15.9 AVIHEALTHCARE 265
15.9.1 COMPANY SNAPSHOT 265
15.9.2 PRODUCT PORTFOLIO 265
15.9.3 RECENT DEVELOPMENTS 266
15.10 BRAUN & CO. LIMITED 267
15.10.1 COMPANY SNAPSHOT 267
15.10.2 PRODUCT PORTFOLIO 267
15.10.3 RECENT DEVELOPMENTS 268
15.11 DAVID 269
15.11.1 COMPANY SNAPSHOT 269
15.11.2 PRODUCT PORTFOLIO 269
15.11.3 RECENT DEVELOPMENTS 270
15.12 GINEVRI SRL 271
15.12.1 COMPANY SNAPSHOT 271
15.12.2 PRODUCT PORTFOLIO 271
15.12.3 RECENT DEVELOPMENTS 272
15.13 IBIS MEDICAL 273
15.13.1 COMPANY SNAPSHOT 273
15.13.2 PRODUCT PORTFOLIO 273
15.13.3 RECENT DEVELOPMENTS 273
15.14 NEOLIGHT 275
15.14.1 COMPANY SNAPSHOT 275
15.14.2 PRODUCT PORTFOLIO 275
15.14.3 RECENT DEVELOPMENTS 275
15.15 NEOMEDLIGHT 277
15.15.1 COMPANY SNAPSHOT 277
15.15.2 PRODUCT PORTFOLIO 277
15.15.3 RECENT DEVELOPMENTS 277
15.16 NICE NANOTECH MEDICAL SYSTEMSPVT. LTD. 278
15.16.1 COMPANY SNAPSHOT 278
15.16.2 PRODUCT PORTFOLIO 278
15.16.3 RECENT DEVELOPMENTS 279
15.17 PHOENIX MEDICAL SYSTEMS (P) LTD 281
15.17.1 COMPANY SNAPSHOT 281
15.17.2 PRODUCT PORTFOLIO 281
15.17.3 RECENT DEVELOPMENTS 281
15.18 S S TECHNOMED (P) LTD 283
15.18.1 COMPANY SNAPSHOT 283
15.18.2 PRODUCT PORTFOLIO 283
15.18.3 RECENT DEVELOPMENT 283
15.19 SHVABE ZURICH GMBH 284
15.19.1 COMPANY SNAPSHOT 284
15.19.2 PRODUCT PORTFOLIO 284
15.19.3 RECENT DEVELOPMENTS 285
15.20 WEYER GMBH 286
15.20.1 COMPANY SNAPSHOT 286
15.20.2 PRODUCT PORTFOLIO 286
15.20.3 RECENT DEVELOPMENT 286
15.21 ZHENGZHOU DISON INSTRUMENT AND METER CO., LTD 287
15.21.1 COMPANY SNAPSHOT 287
15.21.2 PRODUCT PORTFOLIO 287
15.21.3 RECENT DEVELOPMENT 287
16 QUESTIONNAIRE 288
17 RELATED REPORTS 291
Segmentation
Short Description
Global Neonatal Jaundice Management Market, By Management (Diagnosis and Treatment), Type (Primary Care and Secondary Care), Technology (Light-Emitting Diode Light Sources, Fluorescent, Halogen and Fiberoptic), End User (Hospitals, Clinics, Ambulatory Surgical Centers, Home Users and Others), Distribution Channel (Direct Tender, Retail Sales and Third Party Distribution), Country (U.S., Canada, Mexico, Germany, U.K., France, Italy, Spain, Netherlands, Russia, Switzerland, Turkey, Rest of Europe, Japan, China, Australia, India, South Korea, Singapore, Indonesia, Thailand, Malaysia, Philippines, Rest of Asia-Pacific, Brazil, Argentina, Rest of South America, Saudi Arabia, South Africa, UAE, Israel, Egypt and Rest of Middle East and Africa) Industry Trends and Forecast to 2028
Market Definition
Neonatal jaundice is yellow discoloration of the skin and eyes which occurs due to increased level of bilirubin in the blood of infants which is not excreted out from the kidney. There are various risk factors which causes the neonatal jaundice such as genetic factor, maternal factor, perinatal factors, and neonatal factors. It mainly occurs in the baby whose birth is before 38 weeks gestation that is preterm babies and babies having poor feeding. But babies who are born between 35 weeks gestation that is term infants and have jaundice, they can be easily treated without any treatment as the yellow color vanish within few days or weeks.
The symptoms for the neonatal jaundice are yellow skin which mainly appears after second or fourth day of birth. The evaluation for the neonatal jaundice are measure the total serum bilirubin by taking the infant blood and device which is used for measuring the bilirubin that is transcutaneous bilirubinometer (TSB). Phototherapy (PT), exchange transfusion, and intravenous immunoglobulin (IVIG) are some of the treatment that is used for the neonatal jaundice.
Market Segmentation
The neonatal jaundice management market is categorized into five notable segments which are based on the management, type, technology, end user and distribution channel.
On the basis of management, the neonatal jaundice management market is segmented into treatment and diagnosis.
On the basis of type, the neonatal jaundice management market is segmented into primary care and secondary care.
On the basis of technology, the neonatal jaundice management market is segmented into fluorescent, halogen, fiberoptic, light-emitting diode light sources, and others.
On the basis of end user, the neonatal jaundice management market is segmented into hospitals, clinics, ambulatory surgical centers, home users and others.
On the basis of distribution channel, the neonatal jaundice management market is segmented into direct tender, retail sales, and third party distribution.
Market Players
The key market players for the neonatal jaundice management market are listed below:
Atom Medical Corp.
avihealthcare
Ibis Medical
Natus Medical Incorporated.
DAVID
Signify Holding.
Weyer GmbH
nice Neotech Medical Systems Pvt. Ltd.
Phoenix Medical Systems
Aeroflow, Inc.
Zhengzhou Dison Instrument And Meter Co., Ltd
GENERAL ELECTRIC COMPANY
Neolight
Ardo
NeoMedLight
S S TECHNOMED(P)LTD
Drgerwerk AG & Co. KGaA
Braun & Co. Limited
HERBERT WALDMANN GMBH & CO. KG
GINEVRI srl
Shvabe Zurich GmbH
Methodology
Get your pre and post sales queries resolved by our Subject matter experts.
We will assist you to customize the report to fit your research needs.
Our prime focus is to provide qualitative and accurate data.
Feel free to order a sample report before purchase.
Your personal and confidential information is safe and secured.
© 2025 Cognate Lifesciences. All Rights Reserved.